PatrickJFlynnMD

Director of Research, Minnesota Oncology Medical Director, Autologous Bone Marrow & Stem Cell Transplant, Abbott Northwestern Hospital, 1989-Present Principal Investigator, NCI Grant Funded Metro Minnesota CCOP 1985-Present

Join to view full profile

Dr. Flynn is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Flynn's full profile

Already have an account?

Office
2000 North Ave
Northfield, MN 55057
Phone+1 507-646-1300

Fax+1 507-646-1392
Is this information wrong?

Education & Training

University of MinnesotaFellowship, Hematology and Medical Oncology, 1979 - 1983
Hennepin HealthcareResidency, Internal Medicine, 1975 - 1978
University of Minnesota Medical SchoolClass of 1975

Certifications & Licensure

MN State Medical License 1976 - 2019

Awards, Honors, & Recognition

Meaningful Use Stage 1 Certification Centers for Medicare & Medicaid Services, 2012
Super Doctor SuperDoctors.com
Top MD Consumers Checkbook

Clinical Trials

Imatinib Mesylate in Treating Patients With Recurrent Brain Tumor Start of enrollment: 2003 Jun 01
Completed
Phase 1, Phase 2
Pentostatin, Cyclophosphamide, and Rituximab Followed By Campath-1H in Patients With Relapsed or Refractory B-Cell CLL Start of enrollment: 2005 Apr 14
Completed
Phase 2
Zoledronate in Preventing Skeletal (Bone)-Related Events in Men Who Are Receiving Androgen Deprivation Therapy For Prostate Cancer and Bone Metastases Start of enrollment: 2004 Jan 01
Completed
Phase 3
Radiation Therapy (WBI Versus PBI) in Treating Women Who Have Undergone Surgery For Ductal Carcinoma In Situ or Stage I or Stage II Breast Cancer Start of enrollment: 2005 Mar 01
Completed
Not Applicable
Paclitaxel, Polyglutamate Paclitaxel, or Observation in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Peritoneal Cancer, or Fallopian Tube Cancer Start of enrollment: 2005 Mar 21
Active, not recruiting
Phase 3
Combination Chemotherapy and Alemtuzumab in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia Start of enrollment: 2006 Jun 01
Terminated
Phase 2
Cetuximab and/or Bevacizumab Combined With Combination Chemotherapy in Treating Patients With Metastatic Colorectal Cancer Start of enrollment: 2005 Nov 01
Completed
Phase 3
Androgen Ablation Therapy With or Without Chemotherapy in Treating Patients With Metastatic Prostate Cancer Start of enrollment: 2006 Sep 26
Active, not recruiting
Phase 3
Azacitidine With or Without Entinostat in Treating Patients With Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia Start of enrollment: 2006 Aug 01
Completed
Phase 2
Cetuximab, Cisplatin, Fluorouracil, and Radiation Therapy in Treating Patients With Anal Cancer Start of enrollment: 2007 Feb 28
Completed
Phase 2
Chemotherapy With or Without Bevacizumab in Treating Patients With Stage IB, Stage II, or Stage IIIA Non-small Cell Lung Cancer That Was Removed By Surgery Start of enrollment: 2007 Jun 01
Active, not recruiting
Phase 3
Sorafenib Tosylate and Temsirolimus in Treating Patients With Recurrent Glioblastoma Start of enrollment: 2006 Mar 24
Completed
Phase 1, Phase 2
Combination Chemotherapy and Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer Start of enrollment: 2006 Sep 15
Completed
Phase 2
S0500 Treatment Decision Making Based on Blood Levels of Tumor Cells for Metastatic Breast Cancer Treated With Chemo Start of enrollment: 2006 Oct 01
Completed
Phase 3
Surgery With or Without Docetaxel and Leuprolide or Goserelin in Treating Patients With High-Risk Localized Prostate Cancer Start of enrollment: 2007 May 08
Active, not recruiting
Phase 3
Irinotecan, Oxaliplatin, and Capecitabine as First-Line Therapy in Treating Patients With Metastatic or Unresectable Locally Advanced Small Bowel Cancer Start of enrollment: 2007 May 01
Completed
Phase 2
Radiation Therapy With or Without Cisplatin in Treating Patients With Recurrent Endometrial Cancer Start of enrollment: 2008 Feb 25
Active, not recruiting
Phase 2
S0535, Gemtuzumab and Combination Chemotherapy in Treating Patients With Previously Untreated Acute Promyelocytic Leukemia Start of enrollment: 2007 Nov 15
Completed
Phase 2
Everolimus, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Start of enrollment: 2009 Mar 01
Completed
Phase 1, Phase 2
Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia Start of enrollment: 2008 Mar 12
Active, not recruiting
Phase 2
Carboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian, Epithelial, Primary Peritoneal, or Fallopian Tube Cancer Start of enrollment: 2007 Dec 06
Active, not recruiting
Phase 3
Prostate Radiation Therapy or Short-Term Androgen Deprivation Therapy and Pelvic Lymph Node Radiation Therapy With or Without Prostate Radiation Therapy in Treating Patients With a Rising Prostate Specific Antigen (PSA) After Surgery for Prostate Cancer Start of enrollment: 2008 Feb 01
Active, not recruiting
Phase 3
Octreotide Acetate and Recombinant Interferon Alfa-2b or Bevacizumab in Treating Patients With Metastatic or Locally Advanced, High-Risk Neuroendocrine Tumor Start of enrollment: 2007 Dec 01
Active, not recruiting
Phase 3
Chemotherapy With or Without Bevacizumab in Treating Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma Start of enrollment: 2008 Aug 08
Active, not recruiting
Phase 3
Fludarabine and Rituximab With or Without Lenalidomide or Cyclophosphamide in Treating Patients With Symptomatic Chronic Lymphocytic Leukemia Start of enrollment: 2008 Jan 15
Completed
Phase 2
Melphalan, Prednisone, and Thalidomide or Lenalidomide in Treating Patients With Newly Diagnosed Multiple Myeloma Start of enrollment: 2008 Feb 29
Active, not recruiting
Phase 3
Pazopanib Hydrochloride in Treating Patients With Advanced Thyroid Cancer Start of enrollment: 2008 Feb 22
Completed
Phase 2
Safety and Efficacy Comparison of Docetaxel and Ixabepilone in Non Metastatic Poor Prognosis Breast Cancer Start of enrollment: 2007 Sep 01
Completed
Phase 3
Radiation Therapy Regimens in Treating Patients With Limited-Stage Small Cell Lung Cancer Receiving Cisplatin and Etoposide Start of enrollment: 2008 Mar 01
Active, not recruiting
Phase 3
Lenalidomide and Dexamethasone With or Without Bortezomib in Treating Patients With Previously Untreated Multiple Myeloma Start of enrollment: 2008 Apr 01
Active, not recruiting
Phase 3
Capecitabine and Lapatinib Ditosylate With or Without Cixutumumab in Treating Patients With Previously Treated HER2-Positive Stage IIIB-IV Breast Cancer Start of enrollment: 2008 Jul 30
Completed
Phase 2
Sunitinib Malate as Maintenance Therapy in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer Previously Treated With Combination Chemotherapy Start of enrollment: 2008 Jun 15
Completed
Phase 3
Dasatinib in Treating Patients With Locally Advanced or Metastatic Mucosal Melanoma, Acral Melanoma, or Vulvovaginal Melanoma That Cannot Be Removed By Surgery Start of enrollment: 2009 Jul 02
Completed
Phase 2
Obatoclax and Bortezomib in Treating Patients With Relapsed or Refractory Multiple Myeloma Start of enrollment: 2008 Jul 01
Terminated
Phase 1, Phase 2
Saracatinib in Treating Patients With Previously Treated Metastatic Pancreatic Cancer Start of enrollment: 2008 Oct 01
Completed
Phase 2
Radiation Therapy With or Without Trastuzumab in Treating Women With Ductal Carcinoma In Situ Who Have Undergone Lumpectomy Start of enrollment: 2008 Nov 10
Active, not recruiting
Phase 3
Paclitaxel, Nab-paclitaxel, or Ixabepilone With or Without Bevacizumab in Treating Patients With Stage IIIC or Stage IV Breast Cancer Start of enrollment: 2008 Oct 13
Completed
Phase 3
S0809: Capecitabine, Gemcitabine, and RT in Patients w/Cholangiocarcinoma of the Gallbladder or Bile Duct Start of enrollment: 2008 Dec 01
Completed
Phase 2
Paclitaxel and Cisplatin or Topotecan With or Without Bevacizumab in Treating Patients With Stage IVB, Recurrent, or Persistent Cervical Cancer Start of enrollment: 2009 Apr 01
Completed
Phase 3
Pelvic Radiation Therapy or Vaginal Implant Radiation Therapy, Paclitaxel, and Carboplatin in Treating Patients With High-Risk Stage I or Stage II Endometrial Cancer Start of enrollment: 2009 Mar 23
Active, not recruiting
Phase 3
S0816 Fludeoxyglucose F 18-PET/CT Imaging and Combination Chemotherapy With or Without Additional Chemotherapy and G-CSF in Treating Patients With Stage III or Stage IV Hodgkin Lymphoma Start of enrollment: 2009 Jul 01
Completed
Phase 2
Lenalidomide With or Without Epoetin Alfa in Treating Patients With Myelodysplastic Syndrome and Anemia Start of enrollment: 2009 Jan 29
Active, not recruiting
Phase 3
Gossypol Acetic Acid in Treating Patients With Recurrent, Metastatic, or Primary Adrenocortical Cancer That Cannot Be Removed By Surgery Start of enrollment: 2009 Feb 01
Completed
Phase 2
Acute Pain Caused by Paclitaxel in Patients With Cancer Start of enrollment: 2009 Feb 01
Completed
Paclitaxel With or Without Carboplatin and/or Bevacizumab Followed by Doxorubicin and Cyclophosphamide in Treating Patients With Breast Cancer That Can Be Removed by Surgery Start of enrollment: 2009 May 15
Active, not recruiting
Phase 2
Bevacizumab and Sorafenib as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Liver Cancer Start of enrollment: 2009 Apr 01
Completed
Phase 1, Phase 2
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases Start of enrollment: 2008 Dec 01
Completed
Radiation Therapy With Concomitant and Adjuvant Temozolomide Versus Radiation Therapy With Adjuvant PCV Chemotherapy in Patients With Anaplastic Glioma or Low Grade Glioma Start of enrollment: 2009 Sep 01
Recruiting
Phase 3
A Randomized Phase II Study of Cisplatin and Etoposide in Combination With Either Hedgehog Inhibitor GDC-0449 or IGF-1R MOAB IMC-A12 for Patients With Extensive Stage Start of enrollment: 2009 Jul 16
Completed
Phase 2
Collecting Tissue Samples From Patients With Leukemia or Other Blood Disorders Planning to Enroll in an ECOG Leukemia Treatment Clinical Trial Start of enrollment: 2004 Sep 21
Completed
Gemcitabine Hydrochloride and Cisplatin With or Without Bevacizumab in Treating Patients With Advanced Urinary Tract Cancer Start of enrollment: 2009 Jul 15
Completed
Phase 3
S0819: Carboplatin and Paclitaxel With or Without Bevacizumab and/or Cetuximab in Treating Patients With Stage IV or Recurrent Non-Small Cell Lung Cancer Start of enrollment: 2009 Jul 15
Terminated
Phase 3
Paclitaxel and Carboplatin or Ifosfamide in Treating Patients With Newly Diagnosed, Persistent or Recurrent Uterine, Ovarian, Fallopian Tube, or Peritoneal Cavity Cancer Start of enrollment: 2009 Aug 17
Active, not recruiting
Phase 3
Paclitaxel, Carboplatin, and Bevacizumab With or Without Cixutumumab in Treating Patients With Stage IV or Recurrent Non-small Cell Lung Cancer Start of enrollment: 2010 Mar 01
Terminated
Phase 2
Symptom Management in Patients With Recurrent or Persistent Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer Start of enrollment: 2010 Jan 19
Active, not recruiting
Not Applicable
Carboplatin, Paclitaxel, and Bevacizumab With or Without Everolimus in Treating Patients With Metastatic Malignant Melanoma Start of enrollment: 2010 Apr 01
Completed
Phase 2
Chemoembolization With or Without Sorafenib Tosylate in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery Start of enrollment: 2009 Oct 28
Completed
Phase 3
Rosuvastatin in Treating Patients With Stage I or Stage II Colon Cancer That Was Removed By Surgery Start of enrollment: 2010 Mar 01
Terminated
Phase 3
Gemcitabine Hydrochloride and Docetaxel With or Without Bevacizumab in Treating Patients With Advanced or Recurrent Uterine Leiomyosarcoma Start of enrollment: 2009 Nov 01
Terminated
Phase 3
Sorafenib Tosylate With or Without Doxorubicin Hydrochloride in Treating Patients With Locally Advanced or Metastatic Liver Cancer Start of enrollment: 2010 Feb 15
Completed
Phase 3
Seneca Valley Virus-001 After Chemotherapy in Treating Patients With Extensive-Stage Small Cell Lung Cancer Start of enrollment: 2010 Jan 01
Terminated
Phase 2
Gemcitabine Hydrochloride or Pemetrexed Disodium and Carboplatin With or Without Celecoxib in Treating Patients With Advanced Non-Small Cell Lung Cancer Start of enrollment: 2010 Feb 01
Terminated
Phase 3
Bortezomib, Liposomal Doxorubicin Hydrochloride, Dexamethasone, and Cyclophosphamide in Treating Patients With Multiple Myeloma That Relapsed After Autologous Stem Cell Transplant Start of enrollment: 2010 Sep 01
Terminated
Phase 2
Melphalan and Dexamethasone With or Without Bortezomib in Treating Patients With Previously Untreated Systemic Light-Chain Amyloidosis Start of enrollment: 2010 Nov 01
Completed
Phase 3
Irinotecan Hydrochloride and Cetuximab With or Without Ramucirumab in Treating Patients With Advanced Colorectal Cancer With Progressive Disease After Treatment With Bevacizumab-Containing Chemotherapy Start of enrollment: 2011 Jan 18
Completed
Phase 2
Changes in Brain Function in Patients With Stage I, Stage II, Stage III, or Stage IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Who Are Receiving Chemotherapy Start of enrollment: 2010 Apr 01
Completed
Induction Chemotherapy Followed By Cetuximab and Radiation in HPV-Associated Resectable Stage III/IV Oropharynx Cancer Start of enrollment: 2010 Aug 11
Completed
Phase 2
Dinaciclib in Treating Patients With Relapsed or Refractory Multiple Myeloma Start of enrollment: 2009 Jul 01
Completed
Phase 2
Radiation Therapy With or Without Chemotherapy in Patients With Stage I-IIA Cervical Cancer Who Previously Underwent Surgery Start of enrollment: 2010 Apr 12
Active, not recruiting
Phase 3
Bevacizumab or Pemetrexed Disodium Alone or In Combination After Induction Therapy in Treating Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer Start of enrollment: 2010 Oct 25
Completed
Phase 3
S0931, Everolimus in Treating Patients With Kidney Cancer Who Have Undergone Surgery Start of enrollment: 2011 Apr 01
Active, not recruiting
Phase 3
Incidence of Cancer in Women at Increased Genetic Risk of Ovarian Cancer Start of enrollment: 2010 Jun 07
Completed
Paclitaxel With or Without Cixutumumab as Second-Line Therapy in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer Start of enrollment: 2010 Sep 21
Active, not recruiting
Phase 2
Temozolomide or Selumetinib in Treating Patients With Metastatic Melanoma of the Eye Start of enrollment: 2010 Jun 01
Completed
Phase 2
Oxaliplatin, Leucovorin Calcium, and Fluorouracil With or Without Celecoxib in Treating Patients With Stage III Colon Cancer Previously Treated With Surgery Start of enrollment: 2010 Jun 01
Active, not recruiting
Phase 3
Everolimus With or Without Bevacizumab in Treating Patients With Advanced Kidney Cancer That Progressed After First-Line Therapy Start of enrollment: 2010 Sep 15
Terminated
Phase 3
Cediranib Maleate With or Without Lenalidomide for the Treatment of Thyroid Cancer Start of enrollment: 2010 Sep 09
Completed
Phase 1, Phase 2
Everolimus and Octreotide Acetate With or Without Bevacizumab in Treating Patients With Locally Advanced or Metastatic Pancreatic Neuroendocrine Tumors That Cannot Be Removed by Surgery Start of enrollment: 2010 Oct 15
Completed
Phase 2
Early Surgery or Standard Palliative Therapy in Treating Patients With Stage IV Breast Cancer Start of enrollment: 2011 May 16
Completed
Not Applicable
Temsirolimus With or Without Cetuximab in Patients With Recurrent and/or Metastatic Head and Neck Cancer Who Did Not Respond to Previous Therapy Start of enrollment: 2010 Nov 01
Completed
Phase 2
Aldesleukin With or Without Ziv-Aflibercept in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery Start of enrollment: 2011 Jan 18
Completed
Phase 2
Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer Start of enrollment: 2011 Jan 15
Active, not recruiting
Phase 3
Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer Start of enrollment: 2011 Jan 06
Active, not recruiting
Phase 3
PET Scan Imaging in Assessing Response in Patients With Esophageal Cancer Receiving Combination Chemotherapy Start of enrollment: 2011 Jul 01
Completed
Phase 2
Pazopanib Hydrochloride in Treating Patients With Advanced or Progressive Malignant Pheochromocytoma or Paraganglioma Start of enrollment: 2011 May 01
Terminated
Phase 2
S1001 PET-Directed Therapy in Treating Patients With Limited-Stage Diffuse Large B-Cell Lymphoma Start of enrollment: 2011 Sep 01
Completed
Phase 2
Quality of Life and Care Needs of Patients With Persistent or Recurrent Ovarian Cancer, Fallopian Tube Cancer, or Peritoneal Cancer Start of enrollment: 2011 Apr 12
Active, not recruiting
S1106 Rituximab With Combination Chemotherapy or Bendamustine Hydrochloride Followed by Consolidation Chemotherapy and Stem Cell Transplantation in Older Patients With Previously Untreated Mantle Cell Lymphoma Start of enrollment: 2011 Nov 01
Completed
Phase 2
A Study of Brentuximab Vedotin in Relapsed or Refractory Non-Hodgkin Lymphoma Start of enrollment: 2011 Aug 01
Completed
Phase 2
Alisertib in Treating Patients With Relapsed or Refractory Peripheral T-Cell Non-Hodgkin Lymphoma Start of enrollment: 2011 Oct 01
Completed
Phase 2
S1207 Hormone Therapy With or Without Everolimus in Treating Patients With Breast Cancer Start of enrollment: 2013 Sep 12
Active, not recruiting
Phase 3
A Study of Brentuximab Vedotin With Hodgkin Lymphoma (HL) and CD30-expressing Peripheral T-cell Lymphoma (PTCL) Start of enrollment: 2012 Oct 31
Completed
Phase 2
Study to Evaluate Efficacy, Safety, Tolerability, and Pharmacodynamics of Entospletinib in Adults With Relapsed or Refractory Hematologic Malignancies Start of enrollment: 2013 Mar 14
Terminated
Phase 2
Cytarabine and Daunorubicin Hydrochloride or Idarubicin and Cytarabine With or Without Vorinostat in Treating Younger Patients With Previously Untreated Acute Myeloid Leukemia Start of enrollment: 2013 Feb 12
Completed
Phase 3
S1216, Phase III ADT+TAK-700 vs. ADT+Bicalutamide for Metastatic Prostate Cancer Start of enrollment: 2013 Mar 08
Active, not recruiting
Phase 3
Standard or Comprehensive Radiation Therapy in Treating Patients With Early-Stage Breast Cancer Previously Treated With Chemotherapy and Surgery Start of enrollment: 2013 Aug 01
Active, not recruiting
Not Applicable
Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab With or Without Estrogen Deprivation in Treating Patients With Hormone Receptor-Positive, HER2-Positive Operable or Locally Advanced Breast Cancer Start of enrollment: 2014 Jan 15
Active, not recruiting
Phase 3
Gemcitabine Hydrochloride With or Without WEE1 Inhibitor MK-1775 in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Start of enrollment: 2014 Jul 21
Active, not recruiting
Phase 2
Lung-MAP: Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer Start of enrollment: 2014 Jul 08
Completed
Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAF Mutant Melanoma That Cannot Be Removed by Surgery Start of enrollment: 2014 Sep 19
Active, not recruiting
Phase 2
Join now to see all

Publications & Presentations

PubMed

7 citations
A Phase 2 Randomized Placebo-Controlled Adjuvant Trial of GI-4000, a Recombinant Yeast Expressing Mutated RAS Proteins in Patients with Resected Pancreas Cancer.
Peter Muscarella, Tanios Bekaii-Saab, Kristi McIntyre, Alexander S. Rosemurgy, Sharona Ross, Donald A. Richards, William E. Fisher, Patrick J. Flynn, Alicia Mattson, C...> ;Journal of Pancreatic Cancer. 2021 Mar 23
15 citations
An International Phase 2 Study of Pazopanib in Progressive and Metastatic Thyroglobulin Antibody Negative Radioactive Iodine Refractory Differentiated Thyroid Cancer
Keith C. Bible, Michael E. Menefee, Chia Chi Josh Lin, Michael Millward, William J. Maples, Boon Cher Goh, Nina J. Karlin, Madeleine A. Kane, Douglas Adkins, Julian R....> ;Thyroid. 2020 Sep 8
41 citations
CODEL: phase III study of RT, RT + TMZ, or TMZ for newly diagnosed 1p/19q codeleted oligodendroglioma. Analysis from the initial study design.
Kurt A. Jaeckle, Karla V. Ballman, Martin J. van den Bent, Caterina Giannini, Evanthia Galanis, Paul D. Brown, Robert B. Jenkins, J. Gregory Cairncross, Wolfgang Wick,...> ;Neuro-Oncology. 2021 Mar 25
11 citations
Intergroup Randomized Phase III Study of Postoperative Oxaliplatin, 5-Fluorouracil, and Leucovorin Versus Oxaliplatin, 5-Fluorouracil, Leucovorin, and Bevacizumab for ...
A. Bapsi Chakravarthy, Fengmin Zhao, Neal J. Meropol, Patrick J. Flynn, Lynne I. Wagner, Jeff A. Sloan, Robert B. Diasio, Edith P. Mitchell, Paul J. Catalano, Bruce J....> ;The Oncologist. 2020 May 1
377 citations
Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled...
Sandra M Swain, David Miles, Sung Bae Kim, Young-Hyuck Im, Seock-Ah Im, Vladimir Semiglazov, Eva Ciruelos, Andreas Schneeweiss, Sherene Loi, Estefania Monturus, Emma C...> ;The Lancet. Oncology. 2020 Apr 1
192 citations
NSABP B-47/NRG Oncology Phase III Randomized Trial Comparing Adjuvant Chemotherapy With or Without Trastuzumab in High-Risk Invasive Breast Cancer Negative for HER2 by...
Louis Fehrenbacher, Reena S. Cecchini, Charles E. Geyer, Priya Rastogi, Joseph P. Costantino, James N. Atkins, John Crown, Jonathan Polikoff, Jean Francois Boileau, Lo...> ;Journal of Clinical Oncology. 2020 Feb 10
Correction to: Phase I-II trial of imatinib mesylate (Gleevec; STI571) in treatment of recurrent oligodendroglioma and mixed oligoastrocytoma. North central cancer tre...
Jaeckle, K. A.,Anderson, S. K.,Twohy, E. L.,Dixon, J. G.,Giannini, C.,Jenkins, R.,Egorin, M. J.,Sarkaria, J. N.,Brown, P. D.,Flynn, P. J.,Schwerkoske, J.,Buckner, J. C...> ;J. Neurooncol.. 2019 Jun 06
Phase I-II trial of imatinib mesylate (Gleevec; STI571) in treatment of recurrent oligodendroglioma and mixed oligoastrocytoma. North central cancer treatment group st...
Jaeckle, K. A.,Anderson, S. K.,Twohy, E. L.,Dixon, J. G.,Giannini, C.,Jenkins, R.,Egorin, M. J.,Sarkaria, J. N.,Brown, P. D.,Flynn, P. J.,Schwerkoske, J.,Buckner, J. C...> ;J. Neurooncol.. 2019 May 24
54 citations
Randomized, Multicenter, Placebo-Controlled Clinical Trial of Duloxetine Versus Placebo for Aromatase Inhibitor–Associated Arthralgias in Early-Stage Breast Cancer: SW...
N. Lynn Henry, Joseph M. Unger, Anne F. Schott, Louis Fehrenbacher, Patrick J. Flynn, Debra M. Prow, Carl W. Sharer, Gary V. Burton, Charles S. Kuzma, Anna Moseley, Da...> ;Journal of Clinical Oncology. 2017 Nov 14
67 citations
Role of Bone-Modifying Agents in Multiple Myeloma: American Society of Clinical Oncology Clinical Practice Guideline Update
Kenneth C. Anderson, Nofisat Ismaila, Patrick J. Flynn, Susan Halabi, Sundar Jagannath, Mohammed S. Ogaily, Jim Omel, Noopur Raje, G. David Roodman, Gary C. Yee, Rober...> ;Journal of Clinical Oncology. 2018 Jan 17
39 citations
Phase 1/2 trial of temsirolimus and sorafenib in the treatment of patients with recurrent glioblastoma: North Central Cancer Treatment Group Study/Alliance N0572
David Schiff, Kurt A. Jaeckle, S. Keith Anderson, Evanthia Galanis, Caterina Giannini, Jan C. Buckner, Phillip Stella, Patrick J. Flynn, Bradley J. Erickson, John Schw...> ;Cancer. 2018 Apr 1
58 citations
Frontline brentuximab vedotin in combination with dacarbazine or bendamustine in patients aged ≥60 years with HL
Jonathan W. Friedberg, Andres Forero-Torres, Rodolfo Bordoni, Vivian Jean M. Cline, Dipti Patel Donnelly, Patrick J. Flynn, Gregg Olsen, Robert T. Chen, Abraham P. Fon...> ;Blood. 2017 Dec 28
364 citations
Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3...
, , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , ,...> ;The Lancet. Oncology. 2017 Dec 1
32 citations
Long-Term Follow-Up of Cardiac Function and Quality of Life for Patients in NSABP Protocol B-31/NRG Oncology: A Randomized Trial Comparing the Safety and Efficacy of D...
Patricia A. Ganz, Edward H. Romond, Reena S. Cecchini, Priya Rastogi, Charles E. Geyer, Sandra M. Swain, Jong-Hyeon Jeong, Louis Fehrenbacher, Howard M. Gross, Adam Br...> ;Journal of Clinical Oncology. 2017 Oct 26
175 citations
Anthracyclines in early breast Cancer: The ABC Trials—USOR 06-090, NSABP B-46-I/USOR 07132, and NSABP B-49 (NRG Oncology)
Joanne L. Blum, Patrick J. Flynn, Greg Yothers, Lina Asmar, Charles E. Geyer, Samuel A. Jacobs, Nicholas J. Robert, Judith O. Hopkins, Joyce O'Shaughnessy, Chau T. Dan...> ;Journal of Clinical Oncology. 2017 Apr 11
9 citations
Relationship between physician-adjudicated adverse events and patient-reported health-related quality of life in a phase II clinical trial (NCT01143402) of patients wi...
Thomas M. Atkinson, Jennifer L. Hay, Alexander N. Shoushtari, Yuelin Li, Daniel Paucar, Sloane C. Smith, Ragini R. Kudchadkar, Austin Doyle, Jeffrey A. Sosman, Jorge F...> ;Journal of Cancer Research and Clinical Oncology. 2017 Mar 1
51 citations
Combination epigenetic therapy in metastatic colorectal cancer (mCRC) with subcutaneous 5-azacitidine and entinostat: a phase 2 consortium/stand up 2 cancer study.
Nilofer S. Azad, Anthony B. El-Khoueiry, Jun Yin, Ann L. Oberg, Patrick J. Flynn, Douglas Adkins, Anup Sharma, Daniel J. Weisenberger, Thomas M. Brown, Prakriti Medvar...> ;Oncotarget. 2017 Feb 6
57 citations
The association between partner support and psychological distress among prostate cancer survivors in a nationwide study
Charles Kamen, Karen M. Mustian, Charles E. Heckler, Michelle C. Janelsins, Luke J. Peppone, Supriya G. Mohile, James M. McMahon, Raymond S. Lord, Patrick J. Flynn, Ma...> ;Journal of Cancer Survivorship. 2015 Jan 21
4 citations
Effect of ArginMax on sexual functioning and quality of life among female cancer survivors: results of the WFU CCOP Research Base Protocol 97106.
Kathryn M. Greven, L.D. Case, Lawrence Nycum, Patricia Zekan, David D. Hurd, Ernie P. Balcueva, Glenn Mills, Robin Zon, Patrick J. Flynn, David D. Biggs, Edward G. Sha...> ;The Journal of Community and Supportive Oncology. 2015 Mar 1
12 citations
Safety and activity of temsirolimus and bevacizumab in patients with advanced renal cell carcinoma previously treated with tyrosine kinase inhibitors: a phase 2 consor...
Jaime R. Merchan, Rui Qin, Henry C. Pitot, Joel Picus, Glenn Liu, Tom R. Fitch, William J. Maples, Patrick J. Flynn, Briant Fruth, Charles Erlichman> ;Cancer Chemotherapy and Pharmacology. 2015 Jan 3
106 citations
A phase II trial of everolimus, temozolomide, and radiotherapy in patients with newly diagnosed glioblastoma: NCCTG N057K.
Daniel J. Ma, Evanthia Galanis, S. Keith Anderson, David Schiff, Timothy J. Kaufmann, Patrick J. Peller, Caterina Giannini, Paul D. Brown, Joon H. Uhm, Steven McGraw, ...> ;Neuro-Oncology. 2015 Sep 1
A phase II study of AZD2171 (cediranib) in the treatment of patients with acute myeloid leukemia or high-risk myelodysplastic syndrome.
Mattison, R.,Jumonville, A.,Flynn, P. J.,Moreno-Aspitia, A.,Erlichman, C.,LaPlant, B.,Juckett, M. B.> ;Leuk. Lymphoma. 2014 Oct 21
10 citations
Hot flashes severity, complementary and alternative medicine use, and self-rated health in women with breast cancer.
Kavita D. Chandwani, Charles E. Heckler, Supriya G. Mohile, Karen M. Mustian, Michelle C. Janelsins, Luke J. Peppone, Peter Bushunow, Patrick J. Flynn, Gary R. Morrow> ;Explore. 2014 Jul 1
310 citations
Effect of Selumetinib vs Chemotherapy on Progression-Free Survival in Uveal Melanoma: A Randomized Clinical Trial
, , , , , , , , , , , , , , , , , , , , , , , , , , > ;JAMA. 2014 Jun 18
78 citations
A Multicenter Phase 2 Trial of Pazopanib in Metastatic and Progressive Medullary Thyroid Carcinoma: MC057H
Keith C. Bible, Vera J. Suman, Julian R. Molina, Robert C. Smallridge, William J. Maples, Michael E. Menefee, Joseph Rubin, Nina J. Karlin, Kostandinos Sideras, John C...> ;The Journal of Clinical Endocrinology and Metabolism. 2014 Feb 25
Join now to see all

Lectures

Mayo Clinic Oncology Review
Mayo School of Continuous Professional Development, Minneapolis, Minnesota - 7/20/2013

Professional Memberships

American Society of Clinical Oncology - ASCO
Member

Hospital Affiliations

Abbott Northwestern HospitalMinneapolis, Minnesota
Park Nicollet Methodist HospitalMinneapolis, Minnesota
North Memorial Health HospitalMinneapolis, Minnesota
M Health Fairview Southdale HospitalMinneapolis, Minnesota
Northfield Hospital and ClinicsNorthfield, Minnesota
United HospitalSaint Paul, Minnesota